Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2019 | 12-2018 | 09-2018 | 06-2018 | 03-2018 | |
| Sales | 11,665 | 13,315 | 10,613 | 7,565 | 2,553 |
| Cost of Goods | 413 | 435 | 100 | 73 | 25 |
| Gross Profit | 11,252 | 12,880 | 10,513 | 7,492 | 2,528 |
| Operating Expenses | 38,315 | 38,614 | 39,300 | 37,578 | 33,576 |
| Operating Income | -26,650 | -25,299 | -28,687 | -30,013 | -31,023 |
| Interest Expense | 3,731 | 3,768 | 5,386 | 5,112 | 4,826 |
| Other Income | 723 | 184 | 921 | 1,132 | 878 |
| Pre-tax Income | -29,658 | -28,883 | -33,152 | -33,993 | -34,971 |
| Net Income Continuous | -29,658 | -28,883 | -33,152 | -33,993 | -34,971 |
| Net Income | $-29,658 | $-28,883 | $-33,152 | $-33,993 | $-34,971 |
| EPS Basic Total Ops | -1.08 | -1.04 | -1.22 | -1.26 | -1.35 |
| EPS Basic Continuous Ops | -1.08 | -1.05 | -1.22 | -1.26 | -1.35 |
| EPS Diluted Total Ops | -1.08 | -1.04 | -1.22 | -1.26 | -1.35 |
| EPS Diluted Continuous Ops | -1.08 | -1.05 | -1.22 | -1.26 | -1.35 |
| EBITDA(a) | $-26,282 | $-25,278 | $-28,683 | $-30,006 | $-30,640 |